Company intelligence / Profile preview

CO.DON GmbH

Ownership: Private
Development stage: Commercial

Overview

CO.DON has EU-wide marketing authorization for its product Spherox for the regenerative treatment of knee cartilage defects. Over 19,000 patients have been treated with CO.DON products since 1997[5][6].

Therapeutic areas: Rheumatology
Modalities: Cell-based therapiesAutologous cell therapiesCartilage cell implants
Industry: Biotech

Drug pipeline

1 asset

Condrosphere

Beyond the preview

Go deeper on CO.DON GmbH.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CO.DON GmbH.

Explore the full profile